Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
1999-08-19
2001-04-03
Clark, Deborah J. R. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S184100, C424S208100, C424S229100, C424S249100, C435S320100
Reexamination Certificate
active
06210663
ABSTRACT:
FIELD OF THE INVENTION
The field of the invention is modulation of mucosal immunity using systemic and mucosal immunization techniques.
BACKGROUND OF THE INVENTION
The human immune system may be broadly subdivided into two separate, interacting subsystems. The central immune system patrols the inner organs and tissues; and the mucosal immune system provides a defensive barrier against microbes that enter the body through the surfaces of the airways, intestines and urogenital tract. While the central immune system has been the subject of intensive study over the last three decades, knowledge of the mucosal immune system, which in humans covers a surface area of approximately 400 m
2
and is therefore by far the larger of the two systems, remains poor.
Intranasal immunization of a variety of vaccine compositions has been reported to favor the development of B cell responses at distal mucosal sites, for example, resulting in vaginal antibody secretion. Among such vaccines are: a recombinant
Salmonella typhimurium
vaccine expressing a hepatitis virus antigen [Hopkins et al,
Infect. Immun.,
6:3279-3286 (1995)], a streptococcal surface antigen coupled to the cholera toxin (CT) B subunit [Wu and Russell,
Infect. Immun.,
61:314-322 (1993)], an HIV peptide given with CT [Staats et al.,
J. Immunol.,
1:462-472 (1996)], a replication competent adenoviral recombinant expressing a herpes virus antigen [Gallichan and Rosenthal,
Vaccine,
13:1589-1595 (1995)], and a DNA vaccine with CT as an adjuvant [Kuklin et al.,
J. Virol.,
21:3138-3145 (1997)]. However, the limited understanding of the mucosal immune system has hampered the development of efficacious vaccines to numerous important human pathogens which infect the host via the genital tract mucosal surface. Despite the above reports, vaccines which induce effective mucosal immunity, particularly vaccines to induce protective immunity against sexually transmitted pathogens, which infect humans via the mucosa and which constitute major emerging and re-emerging infectious diseases, are not currently available.
Such agents include human immunodeficiency virus (HIV), human papilloma viruses (HPV),
Neisseria gonorrhea, Treponema pallidum,
and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). These agents often establish persistent infections once they have avoided the mucosal barrier. Further, systemic immunization capable of protecting against a systemic infection may not protect against a mucosal infection [Lehner et al.,
Nature Med.,
2:767-775 (1996)]. Accordingly, systemic immunization represents a secondary (and possibly ineffective) means of defense once the first line of defense, i.e., mucosal immunity, has been breached.
Vaccine compositions which have been administered systemically or mucosally include adenovirus constructs that express reporter proteins, upon either intravenous inoculation targeting the liver or upon intratracheal application targeting the lung. However, a strong neutralizing antibody response to the adenoviral antigens of the recombinant adenovirus often reduces the rate of infection upon a second application of such recombinant adenovirus as a vaccine construct. These vaccine constructs induce CD8+ T cells reactive to both the reporter transgene protein product and to the viral antigens of the adenoviral construct. This immune response causes clearance of recombinant adenovirus-infected cells from the animal within 10-14 days post-inoculation [Yang et al., 1995,
J. Virol.,
69:2004-2015; Yang et al., 1995,
Gene Therapy,
3:137-144]. Adenoviral recombinants also stimulate CD4+ T helper cells, predominantly of the Th1 type. These T helper cells promote activation of an antibody response which prevents efficacious re-infection upon a second application of the adenoviral vaccine vehicle. Accordingly, the strong immune response to the adenovirus vaccine vehicle curtails the necessary secondary immune response to the antigen product expressed by the recombinant vaccine upon booster immunization.
In order to circumvent this limitation of adenoviral recombinant vectors, genetic vaccines based on plasmid vectors have been tested for their ability to induce a protective immune response in animals. In this regard, prior studies have demonstrated that plasmid-based vaccines, upon systemic application, prime the systemic immune system to a second systemic immunization with a traditional antigen, such as a protein or a recombinant virus [Xiang et al,
Springer Semin. Immunopathol.,
19:257-268 (1997); J. Schneider et al,
Nature Med.,
4:397 (1998); M. Sedeguh et al.,
Proc. Natl. Acad. Sci., USA;
95:7648 (1998)]. However, these plasmid-based vaccines appear to induce only low levels of genital IgA secretion upon co-administration with cholera toxin [Kuklin et al.,
J. Virol.,
71:3138-3145 (1997)]. Therefore, plasmid-based vaccines, while useful for inducing a systemic immune response, may not be adequate for the purposes of generating a protective mucosal immune response.
There is a long-felt and acute need for the design and development of efficacious vaccines to induce or confer mucosal immunity in humans to human pathogens. The present invention satisfies this need.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to a method of inducing mammalian mucosal immunity to a pathogen. The method includes the steps of:
(a) administering via a non-mucosal route of administration an effective amount of a priming DNA vaccine composition which comprises a DNA sequence encoding an antigen of the pathogen. This DNA vaccine may be simply the DNA encoding the antigen, the DNA encoding the antigen under the control of regulatory sequences directing expression thereof in a mammalian cell, or such DNA sequences in a plasmid or vector containing other nucleotide sequences; and
(b) subsequently administering intranasally to the mammal an effective amount of a boosting vaccine composition which comprises the antigen in protein form, fragments thereof, a DNA sequence encoding the antigen, and optionally under the control of a regulatory sequence directing expression thereof in a mammalian cell, or a bacterial or viral carrier comprising the DNA sequence encoding the antigen.
In another aspect, the invention provides a method of reducing the unwanted immune response to a recombinant vaccine vehicle or carrier. A priming DNA vaccine composition is administered, which comprises a DNA sequence encoding an antigen of a pathogen under the optional control of regulatory sequences directing expression thereof in a mammalian cell. Significantly, this DNA vaccine contains no sequences encoding antigenic proteins or peptides of the vaccine vehicle outside of the antigen-encoding and regulatory sequences. This DNA vaccine is administered prior to administering a recombinant vaccine vehicle. The recombinant vaccine composition comprises a recombinant virus or bacteria encoding a DNA sequence encoding the same antigen under the control of a regulatory sequence directing expression of the antigen in a mammalian cell or tissue. Upon administration of the recombinant vaccine, the immune response to the antigen is enhanced and the immune response to the recombinant vehicle is reduced.
In still another aspect, this invention provides a kit for inducing mucosal immunity in mammals. This kit contains the priming DNA vaccine composition described above; a boosting vaccine composition described above; as well as instructions for the use of the kit. In another embodiment, the kit comprises a co-priming amount of a genetic adjuvant. In still another embodiment, the kit contains an applicator for delivering the priming composition to the mammal via a non-mucosal route, and/or an applicator for delivering the boosting composition to the mammal mucosally, preferably intranasally.
REFERENCES:
patent: 4393201 (1983-07-01), Curtis et al.
patent: 5698202 (1997-12-01), Ertl et al.
Whittle et al. J. Med. Microbiol. 46:1029-1038, Dec. 1997.*
Sasa
Clark Deborah J. R.
Howson and Howson
Stroup Carrie
The Wistar Institute of Anatomy and Biology
LandOfFree
Methods of augmenting mucosal immunity through systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of augmenting mucosal immunity through systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of augmenting mucosal immunity through systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2469300